A-485 and B029-2 are two selective and highly potent p300 inhibitors that suppress tumor cell metabolism and tumor progression by targeting p300/CBP and reducing the levels of key metabolic enzyme genes, such as PSPH, PSAT1 promoter region H3K18Ac, and H3K27Ac. The gene discussed is EIF4E; the disease is neoplasm.